Publication:
Comparisons of methamphetamine psychotic and schizophrenic symptoms: A differential item functioning analysis

dc.contributor.authorManit Srisurapanonten_US
dc.contributor.authorSuwanna Arunpongpaisalen_US
dc.contributor.authorKiyoshi Wadaen_US
dc.contributor.authorJohn Marsdenen_US
dc.contributor.authorRobert Alien_US
dc.contributor.authorRonnachai Kongsakonen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherKhon Kaen Universityen_US
dc.contributor.otherNational Institute of Mental Healthen_US
dc.contributor.otherKing's College Londonen_US
dc.contributor.otherUniversity of Adelaideen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-05-03T08:39:55Z
dc.date.available2018-05-03T08:39:55Z
dc.date.issued2011-06-01en_US
dc.description.abstractThe concept of negative symptoms in methamphetamine (MA) psychosis (e.g., poverty of speech, flatten affect, and loss of drive) is still uncertain. This study aimed to use differential item functioning (DIF) statistical techniques to differentiate the severity of psychotic symptoms between MA psychotic and schizophrenic patients. Data of MA psychotic and schizophrenic patients were those of the participants in the WHO Multi-Site Project on Methamphetamine-Induced Psychosis (or WHO-MAIP study) and the Risperidone Long-Acting Injection in Thai Schizophrenic Patients (or RLAI-Thai study), respectively. To confirm the unidimensionality of psychotic syndromes, we applied the exploratory and confirmatory factor analyses (EFA and CFA) on the eight items of Manchester scale. We conducted the DIF analysis of psychotic symptoms observed in both groups by using nonparametric kernel-smoothing techniques of item response theory. A DIF composite index of 0.30 or greater indicated the difference of symptom severity. The analyses included the data of 168 MA psychotic participants and the baseline data of 169 schizophrenic patients. For both data sets, the EFA and CFA suggested a three-factor model of the psychotic symptoms, including negative syndrome (poverty of speech, psychomotor retardation and flatten/incongruous affect), positive syndrome (delusions, hallucinations and incoherent speech) and anxiety/depression syndrome (anxiety and depression). The DIF composite indexes comparing the severity differences of all eight psychotic symptoms were lower than 0.3. The results suggest that, at the same level of syndrome severity (i.e., negative, positive, and anxiety/depression syndromes), the severity of psychotic symptoms, including the negative ones, observed in MA psychotic and schizophrenic patients are almost the same. © 2011 Elsevier Inc.en_US
dc.identifier.citationProgress in Neuro-Psychopharmacology and Biological Psychiatry. Vol.35, No.4 (2011), 959-964en_US
dc.identifier.doi10.1016/j.pnpbp.2011.01.014en_US
dc.identifier.issn18784216en_US
dc.identifier.issn02785846en_US
dc.identifier.other2-s2.0-79956040605en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/12787
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79956040605&origin=inwarden_US
dc.subjectNeuroscienceen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleComparisons of methamphetamine psychotic and schizophrenic symptoms: A differential item functioning analysisen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79956040605&origin=inwarden_US

Files

Collections